The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. Read the full story
The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. Read the full story
Genmab, a top big biotech company, headquartered in Denmark is one of the leaders today in the human antibody therapeutics market for cancer treatment. Read the full story
MorphoSys, a leader in antibody drug discovery, has emerged as a top 50 big biotech company with its product pipeline and partnering strategy. Read the full story
Genmab is an internationally recognised biotechnology company developing human antibody therapeutics primarily for cancer. Read the full story
Morphosys is a leading biotechnology developing therapeutic antibodies for a range of different indications. Read the full story
Seattle Genetics is a biotech company developing and commercializing antibody-based therapeutics to improve the lives of people living with cancer. Read the full story
Seattle Genetics, a successful big biotech industry headquartered in Seattle, focuses its effort on advancing antibody drug conjugate technology targeted toward cancer treatment. Read the full story
Mersana Therapeutics and Merck KGaA announced an biotech partnering to collaboratively develop next-generation antibody-drug conjugates (ADCs) for $792 million. Read the full story
Antibodies are the subject of numerous partnering deals every year, here we provide a review of recent partnering trends activity. Read the full story
PDL Biopharma based in Nevada manages patents associated with its humanized monoclonal antibodies technology. Read the full story